FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327545326> ?p ?o ?g. }

• W4327545326 endingPage "45S" @default.
• W4327545326 startingPage "44S" @default.
• W4327545326 abstract "Report preliminary results from the vacuum-assisted sclerotherapy catheter (VASC) postmarket clinical follow-up study, a multicenter, prospective, nonrandomized trial with the primary objective to confirm safety and efficacy of the Velex (I-VASC S.r.l., Milan, Italy) empty vein ablation (EVA) system in the treatment of the great saphenous vein (GSV) (registered on ClinicalTrials.gov, ID: NCT05581524). Blood flow is considered a limitation for sclerotherapeutic and endovascular treatment of diseased veins. Velex is the first minimally invasive device for endovascular treatment of varicose veins by EVA—a nonthermal, nontumescent technique with good in vivo results in preclinical study. EVA consists of a chemical ablation with low polidocanol concentration, and full control of the contact time between drug and the venous wall. After inflating a long central balloon that removes the blood from the segment intended to treat, isolating it with two lateral balloons, and injecting the drug (simultaneously deflating the central balloon), the catheter can be pulled back to treat the entire length of the vein (Figure, A, B). In total, 24 to 36 patients affected by chronic venous insufficiency of the GSV will be enrolled in two participating centers. The primary endpoint is vein occlusion evaluated intraoperatively with duplex ultrasound examination at postoperative day 7, and at three months and six months. Minor and major adverse events will be recorded. The secondary endpoint is evaluation of pain score during the procedure. A quality-of-life questionnaire will be filled in preoperatively and at three-monthly visits for comparative analysis. Main exclusion criteria are GSV standing diameter of >12 mm for vein segments longer than 3 cm, or diameter of <4 mm for segments >5 cm. From June 14, 2022, eight patients (six female; mean age, 52 years) underwent EVA treatment of the GSV using Velex. Based on data confirmed and available at the time of abstract submission, maximum GSV diameter was 10.5 mm (mean, 8.1 mm). Notably, the GSV was completely occluded in the whole treated segment according to intraoperative duplex ultrasound control. A shrinkage of GSV diameter was observed at 7 days, 1 month, and 3 months (Table; Figure, C). Mean pain score was 3. No major adverse events occurred. Although these results are very preliminary, outcomes at 1 and 3 months suggest that Velex could be very effective for nonthermal, nontumescent endovascular treatment of superficial venous insufficiency by EVA.TableGSV diameter at duplex ultrasound examination performed at different levels of the thigh: Baseline, at postoperative day 7, and at the 1- and 3-month follow-upsParameterPatient 1 45 yearsPatient 2 73 yearsPatient 3 53 yearsPatient 4 32 yearsPatient 5 55 yearsPatient 6 65 yearsPatient 7 33 yearsPatient 8 63 yearsBaseline Proximal vein diameter5.57.576.56.86.46.88 Maximum caliber1010.58.577.27.579.7 Mid/distal-thigh vein diameter8.38.5977.46.85.67.1 Maximum caliber10109.87.48.97.1687-Day follow-up Mean proximal vein diameter56.5 Mean mid/distal-thigh vein diameter47 Complete closureYesYesaaaaa1-Month follow-up Mean proximal vein diameter56.7 Mean mid/distal-thigh vein diameter4.56.1 Complete closureYesYesaaaaa3-Month follow-up Mean proximal vein diameter3.34.7 Mean mid/distal-thigh vein diameter3.54.7 Complete closureYes, slight reperfusion of 4 cm of GSV at proximal thigh, but without refluxYes, slight reperfusion of 5 cm of GSV at proximal thigh with <1 second refluxaaaaaaa Data to be confirmed or were not reported at the time of abstract submission. Open table in a new tab" @default.
• W4327545326 created "2023-03-17" @default.
• W4327545326 creator A5008977908 @default.
• W4327545326 creator A5027109990 @default.
• W4327545326 creator A5031384794 @default.
• W4327545326 creator A5068473771 @default.
• W4327545326 creator A5077602287 @default.
• W4327545326 date "2023-04-01" @default.
• W4327545326 modified "2023-09-24" @default.
• W4327545326 title "Vacuum-assisted Sclerotherapy Catheter Study on Velex for Endovascular-Nonthermal, Nontumescent Empty Vein Ablation: Preliminary Results of the World's First Clinical Trial" @default.
• W4327545326 doi "https://doi.org/10.1016/j.jvs.2023.01.126" @default.
• W4327545326 hasPublicationYear "2023" @default.
• W4327545326 type Work @default.
• W4327545326 citedByCount "0" @default.
• W4327545326 crossrefType "journal-article" @default.
• W4327545326 hasAuthorship W4327545326A5008977908 @default.
• W4327545326 hasAuthorship W4327545326A5027109990 @default.
• W4327545326 hasAuthorship W4327545326A5031384794 @default.
• W4327545326 hasAuthorship W4327545326A5068473771 @default.
• W4327545326 hasAuthorship W4327545326A5077602287 @default.
• W4327545326 hasBestOaLocation W43275453261 @default.
• W4327545326 hasConcept C126322002 @default.
• W4327545326 hasConcept C126838900 @default.
• W4327545326 hasConcept C141071460 @default.
• W4327545326 hasConcept C168563851 @default.
• W4327545326 hasConcept C203092338 @default.
• W4327545326 hasConcept C2776106345 @default.
• W4327545326 hasConcept C2776268601 @default.
• W4327545326 hasConcept C2777202286 @default.
• W4327545326 hasConcept C2777475103 @default.
• W4327545326 hasConcept C2778230777 @default.
• W4327545326 hasConcept C2778902805 @default.
• W4327545326 hasConcept C2779480337 @default.
• W4327545326 hasConcept C2780950165 @default.
• W4327545326 hasConcept C2781267111 @default.
• W4327545326 hasConcept C2993470428 @default.
• W4327545326 hasConcept C535046627 @default.
• W4327545326 hasConcept C71924100 @default.
• W4327545326 hasConceptScore W4327545326C126322002 @default.
• W4327545326 hasConceptScore W4327545326C126838900 @default.
• W4327545326 hasConceptScore W4327545326C141071460 @default.
• W4327545326 hasConceptScore W4327545326C168563851 @default.
• W4327545326 hasConceptScore W4327545326C203092338 @default.
• W4327545326 hasConceptScore W4327545326C2776106345 @default.
• W4327545326 hasConceptScore W4327545326C2776268601 @default.
• W4327545326 hasConceptScore W4327545326C2777202286 @default.
• W4327545326 hasConceptScore W4327545326C2777475103 @default.
• W4327545326 hasConceptScore W4327545326C2778230777 @default.
• W4327545326 hasConceptScore W4327545326C2778902805 @default.
• W4327545326 hasConceptScore W4327545326C2779480337 @default.
• W4327545326 hasConceptScore W4327545326C2780950165 @default.
• W4327545326 hasConceptScore W4327545326C2781267111 @default.
• W4327545326 hasConceptScore W4327545326C2993470428 @default.
• W4327545326 hasConceptScore W4327545326C535046627 @default.
• W4327545326 hasConceptScore W4327545326C71924100 @default.
• W4327545326 hasIssue "4" @default.
• W4327545326 hasLocation W43275453261 @default.
• W4327545326 hasOpenAccess W4327545326 @default.
• W4327545326 hasPrimaryLocation W43275453261 @default.
• W4327545326 hasRelatedWork W2038891247 @default.
• W4327545326 hasRelatedWork W2059926466 @default.
• W4327545326 hasRelatedWork W2089480126 @default.
• W4327545326 hasRelatedWork W3009755280 @default.
• W4327545326 hasRelatedWork W3010816387 @default.
• W4327545326 hasRelatedWork W3028672170 @default.
• W4327545326 hasRelatedWork W3163474218 @default.
• W4327545326 hasRelatedWork W4200314199 @default.
• W4327545326 hasRelatedWork W4206709034 @default.
• W4327545326 hasRelatedWork W4287829014 @default.
• W4327545326 hasVolume "77" @default.
• W4327545326 isParatext "false" @default.
• W4327545326 isRetracted "false" @default.
• W4327545326 workType "article" @default.